Compare $CBIO vs $MNPR | Chartloom

Compare

$CBIO vs $MNPR

Crescent Biopharma Inc · Monopar Therapeutics Inc

CBIO

Crescent Biopharma Inc

MNPR

Monopar Therapeutics Inc

Compare $CBIO vs $MNPR

Comparing Crescent Biopharma Inc and Monopar Therapeutics Inc

CBIOCrescent Biopharma Inc

MNPRMonopar Therapeutics Inc

CBIOCrescent Biopharma Inc

Market cap

$532M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

34.6%

52W performance

23.6%

FCF yield

-28.9%

MNPRMonopar Therapeutics Inc

Market cap

$529M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

48.37x

Rev growth (TTM)

—

YTD performance

19.6%

52W performance

-19.9%

FCF yield

-2.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CBIO

MNPR

Detailed metrics comparison

CBIO

Crescent Biopharma Inc

MNPR

Monopar Therapeutics Inc

Market Cap

CBIO$532M

MNPR$529M

Enterprise Value

CBIO$360M

MNPR$476M

Price

CBIO$14.91

MNPR$78.96

P/E Ratio

CBION/A

MNPRN/A

P/S Ratio

CBIO44.76x

MNPR0.00x

EV/Sales

CBIO30.32x

MNPR0.00x

EV/EBITDA

CBIO0.00x

MNPR0.00x

P/B Ratio

CBIO3.26x

MNPR4.00x

P/FCF Ratio

CBION/A

MNPRN/A

EV/FCF

CBIO-2.35x

MNPR-39.10x

PEG Ratio

CBION/A

MNPRN/A

Forward P/E (NTM)

CBION/A

MNPRN/A

Forward P/S (NTM)

CBION/A

MNPR48.37x

Revenue (TTM)

CBIO$12M

MNPR$0

Revenue Growth (YoY)

CBION/A

MNPRN/A

Forward Rev Growth

CBIO-15.7%

MNPR327.6%

Gross Margin (TTM)

CBIO0.0%

MNPR0.0%

Operating Margin (TTM)

CBIO0.0%

MNPR0.0%

EBITDA Margin (TTM)

CBIO-1355.3%

MNPR0.0%

Net Margin (TTM)

CBIO-1406.4%

MNPR0.0%

FCF Margin (TTM)

CBIO-1292.8%

MNPRN/A

Net Income (TTM)

CBIO$-167M

MNPR$-18M

FCF (TTM)

CBIO$-154M

MNPR$-12M

EPS (TTM)

CBIO-$5.47

MNPR-$2.09

ROE (TTM)

CBIO-10026.0%

MNPR-1308.0%

ROA (TTM)

CBIO-8791.0%

MNPR-1279.0%

ROIC (TTM)

CBIO-10026.0%

MNPR-1308.0%

Cash

CBIO$172M

MNPR$53M

Debt

CBIO$0

MNPR$0

Net Cash/Debt

CBIO$172M

MNPR$53M

Current Ratio (TTM)

CBIO9.66x

MNPR33.56x

Quick Ratio (TTM)

CBIO9.26x

MNPR33.56x

Debt/Equity (TTM)

CBIO0.00x

MNPR0.00x

Debt/Assets (TTM)

CBIO0.0%

MNPR0.0%

Interest Coverage (TTM)

CBION/A

MNPRN/A

Net Debt/EBITDA (TTM)

CBIO0.00x

MNPR0.00x

Beta

CBIO1.39

MNPR1.54

52W Performance

CBIO23.6%

MNPR-19.9%

YTD Performance

CBIO34.6%

MNPR19.6%

% from 52W High

CBIO-45.6%

MNPR-36.7%

% from 52W Low

CBIO71.0%

MNPR57.7%

Asset Turnover (TTM)

CBIO0.05x

MNPR0.00x

FCF Yield (TTM)

CBIO-28.9%

MNPR-2.3%

Earnings Yield (TTM)

CBIO-31.4%

MNPR-3.4%

Dividend Yield (TTM)

CBION/A

MNPRN/A

Rule of 40

CBIO-1,292.8

MNPR0.0

EV/GP/RG

CBION/A

MNPRN/A

Ticker research

View CBIO research View MNPR research

Metric	CBIO Crescent Biopharma Inc	MNPR Monopar Therapeutics Inc
Market & Valuation
Market Cap	$532M	$529M
Enterprise Value	$360M	$476M
Price	$14.91	$78.96
P/E Ratio	N/A	N/A
P/S Ratio	44.76x	0.00x
EV/Sales	30.32x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.26x	4.00x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.35x	-39.10x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	48.37x
Revenue & Growth
Revenue (TTM)	$12M	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	-15.7%	327.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1355.3%	0.0%
Net Margin (TTM)	-1406.4%	0.0%
FCF Margin (TTM)	-1292.8%	N/A
Net Income (TTM)	$-167M	$-18M
FCF (TTM)	$-154M	$-12M
EPS (TTM)	-$5.47	-$2.09
ROE (TTM)	-10026.0%	-1308.0%
ROA (TTM)	-8791.0%	-1279.0%
ROIC (TTM)	-10026.0%	-1308.0%
Financial Health
Cash	$172M	$53M
Debt	$0	$0
Net Cash/Debt	$172M	$53M
Current Ratio (TTM)	9.66x	33.56x
Quick Ratio (TTM)	9.26x	33.56x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.39	1.54
52W Performance	23.6%	-19.9%
YTD Performance	34.6%	19.6%
% from 52W High	-45.6%	-36.7%
% from 52W Low	71.0%	57.7%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.00x
FCF Yield (TTM)	-28.9%	-2.3%
Earnings Yield (TTM)	-31.4%	-3.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,292.8	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CBIO research	View MNPR research

Valuation

P/S Ratio

MNPR

0.00x

CBIO

44.76x

EV/FCF

MNPR

-39.10x

CBIO

-2.35x

Growth & revenue

Forward Revenue Growth

MNPR

327.6%

CBIO

-15.7%

Profitability & performance

Gross Margin

CBIO

0.0%

MNPR

0.0%

ROE

MNPR

-1308.0%

CBIO

-10026.0%

FCF Yield %

MNPR

-2.3%

CBIO

-28.9%

52-Week Performance

CBIO

23.6%

MNPR

-19.9%

Detailed metrics comparison

CBIO

Crescent Biopharma Inc

MNPR

Monopar Therapeutics Inc

Market Cap

CBIO$532M

MNPR$529M

Enterprise Value

CBIO$360M

MNPR$476M

Price

CBIO$14.91

MNPR$78.96

P/E Ratio

CBION/A

MNPRN/A

P/S Ratio

CBIO44.76x

MNPR0.00x

EV/Sales

CBIO30.32x

MNPR0.00x

EV/EBITDA

CBIO0.00x

MNPR0.00x

P/B Ratio

CBIO3.26x

MNPR4.00x

P/FCF Ratio

CBION/A

MNPRN/A

EV/FCF

CBIO-2.35x

MNPR-39.10x

PEG Ratio

CBION/A

MNPRN/A

Forward P/E (NTM)

CBION/A

MNPRN/A

Forward P/S (NTM)

CBION/A

MNPR48.37x

Revenue (TTM)

CBIO$12M

MNPR$0

Revenue Growth (YoY)

CBION/A

MNPRN/A

Forward Rev Growth

CBIO-15.7%

MNPR327.6%

Gross Margin (TTM)

CBIO0.0%

MNPR0.0%

Operating Margin (TTM)

CBIO0.0%

MNPR0.0%

EBITDA Margin (TTM)

CBIO-1355.3%

MNPR0.0%

Net Margin (TTM)

CBIO-1406.4%

MNPR0.0%

FCF Margin (TTM)

CBIO-1292.8%

MNPRN/A

Net Income (TTM)

CBIO$-167M

MNPR$-18M

FCF (TTM)

CBIO$-154M

MNPR$-12M

EPS (TTM)

CBIO-$5.47

MNPR-$2.09

ROE (TTM)

CBIO-10026.0%

MNPR-1308.0%

ROA (TTM)

CBIO-8791.0%

MNPR-1279.0%

ROIC (TTM)

CBIO-10026.0%

MNPR-1308.0%

Cash

CBIO$172M

MNPR$53M

Debt

CBIO$0

MNPR$0

Net Cash/Debt

CBIO$172M

MNPR$53M

Current Ratio (TTM)

CBIO9.66x

MNPR33.56x

Quick Ratio (TTM)

CBIO9.26x

MNPR33.56x

Debt/Equity (TTM)

CBIO0.00x

MNPR0.00x

Debt/Assets (TTM)

CBIO0.0%

MNPR0.0%

Interest Coverage (TTM)

CBION/A

MNPRN/A

Net Debt/EBITDA (TTM)

CBIO0.00x

MNPR0.00x

Beta

CBIO1.39

MNPR1.54

52W Performance

CBIO23.6%

MNPR-19.9%

YTD Performance

CBIO34.6%

MNPR19.6%

% from 52W High

CBIO-45.6%

MNPR-36.7%

% from 52W Low

CBIO71.0%

MNPR57.7%

Asset Turnover (TTM)

CBIO0.05x

MNPR0.00x

FCF Yield (TTM)

CBIO-28.9%

MNPR-2.3%

Earnings Yield (TTM)

CBIO-31.4%

MNPR-3.4%

Dividend Yield (TTM)

CBION/A

MNPRN/A

Rule of 40

CBIO-1,292.8

MNPR0.0

EV/GP/RG

CBION/A

MNPRN/A

Ticker research

View CBIO research View MNPR research

Metric	CBIO Crescent Biopharma Inc	MNPR Monopar Therapeutics Inc
Market & Valuation
Market Cap	$532M	$529M
Enterprise Value	$360M	$476M
Price	$14.91	$78.96
P/E Ratio	N/A	N/A
P/S Ratio	44.76x	0.00x
EV/Sales	30.32x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.26x	4.00x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.35x	-39.10x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	48.37x
Revenue & Growth
Revenue (TTM)	$12M	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	-15.7%	327.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1355.3%	0.0%
Net Margin (TTM)	-1406.4%	0.0%
FCF Margin (TTM)	-1292.8%	N/A
Net Income (TTM)	$-167M	$-18M
FCF (TTM)	$-154M	$-12M
EPS (TTM)	-$5.47	-$2.09
ROE (TTM)	-10026.0%	-1308.0%
ROA (TTM)	-8791.0%	-1279.0%
ROIC (TTM)	-10026.0%	-1308.0%
Financial Health
Cash	$172M	$53M
Debt	$0	$0
Net Cash/Debt	$172M	$53M
Current Ratio (TTM)	9.66x	33.56x
Quick Ratio (TTM)	9.26x	33.56x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.39	1.54
52W Performance	23.6%	-19.9%
YTD Performance	34.6%	19.6%
% from 52W High	-45.6%	-36.7%
% from 52W Low	71.0%	57.7%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.00x
FCF Yield (TTM)	-28.9%	-2.3%
Earnings Yield (TTM)	-31.4%	-3.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,292.8	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CBIO research	View MNPR research